 92.8% (482/
520) after EVLA; 3-year
follow-up; no
neurologic or cardiac
adverse events after
PEM

Retrospective
cohort study

AAGSV, Anterior accessory great saphenous vein; AVSS, Aberdeen Varicose Vein Symptom Severity; AVVQ, Aberdeen Varicose Vein Questionnaire;
CAC, cyanoacrylate closure; EV